In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
Where this comes from
- Record sourced from PubMed, PMID 37782925.
- Also identified by DOI 10.7326/J23-0077.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wharton S, Blevins T, Connery L, et al; GZGI investigators. <b>Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.</b> N Engl J Med. 2023;389:877-880. 37351564.
Medical subject headings
- Overweight
- Diabetes Mellitus, Type 2